Navigation Links
Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
Date:1/27/2011

asone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a $1.2 million FDA Orphan Products Grant-supported confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD. Soligenix is also conducting a National Cancer Institute (NCI)-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, RiVax™, and LPM™, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be red
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
2. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
3. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
4. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
5. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
8. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
9. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
10. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
11. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
(Date:9/17/2014)... 17 2014 IBM (NYSE: IBM ) ... IBM technical computing and storage technology to accelerate ... These services deliver critically important information to help ... unique cancer, which could lead to better health ... in general. Today, optimal cancer care ...
(Date:9/17/2014)... , September 17, 2014 ... to congratulate Biocartis commitment in shipping its first ... long-time investor in Biocartis as part of Debiopharm ... fully automated, real-time PCR based molecular diagnostics system, ... access to clinical molecular diagnostic information, anywhere and ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 2Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 3Caris Life Sciences Selects IBM to Accelerate Use of Molecular Profiling in Cancer Treatment Selection 4Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument 2
... - NanoViricides,Inc. (Pink Sheets: NNVC) discussed today the ... presented along with the,successful BSL3 in vitro studies ... Annual Symposium of the Pan American Society for ... (Pan American Society,for Clinical Virology (PASCV): Clinical Virology ...
... and Symptom Severity; New,Resources for Patients, Parents, WASHINGTON, ... today by the National Consumers League shows that ... days. Four in,ten asthma sufferers understand asthma medication ... recent the diagnosis, the less,knowledgeable adult patients tend ...
Cached Medicine Technology:Global Rabies Treatment May be Possible with NanoViricides Drugs 2New Survey Finds Troubling Data on American Asthma Sufferers 2New Survey Finds Troubling Data on American Asthma Sufferers 3New Survey Finds Troubling Data on American Asthma Sufferers 4New Survey Finds Troubling Data on American Asthma Sufferers 5New Survey Finds Troubling Data on American Asthma Sufferers 6
(Date:9/17/2014)... Thomas A. Sellers, Ph.D., M.P.H., Jong Park, Ph.D. and Hui-Yi ... that influence the risk for developing prostate cancer, according to ... , Prostate cancer is the most common non-skin cancer in ... with the disease in his lifetime. Family history is the ... brother or father with prostate cancer is twice as likely ...
(Date:9/17/2014)... People with facial paralysis are perceived as being ... universal language of facial expression, a new study from ... The findings highlight the important role the face plays ... prejudice against those with facial paralysis because of their ... in the College of Liberal Arts at Oregon State ...
(Date:9/17/2014)... Tools4ever, the market leader ... and Boston Software Systems, leader in healthcare ... Under the agreement, Tools4ever will use ... within its identity and password management solutions. ... automation platforms that streamline complex processes and ...
(Date:9/17/2014)... September 17, 2014. Kessler Foundation is the recipient ... the International Progressive Multiple Sclerosis (MS) Alliance. ... Traumatic Brain Injury Research, is principal investigator of ... of cognitive rehabilitation in individuals with progressive multiple ... grants awarded by the Alliance to investigators in ...
(Date:9/17/2014)... Gerontological Society of America (GSA) invites all journalists ... the country,s largest interdisciplinary conference in the field ... Washington, DC. Media representatives may register free of charge. ... the five-day gathering at the Walter E. Washington Convention ... 2014 is "Making Connections: From Cells to Societies" and ...
Breaking Medicine News(10 mins):Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2
... ... Innovation and Growth , ... (PRWEB) June 21, 2010 -- DKI Direct ( http://www.dkidirect.com ), a leading Patient ... Chief Marketing Officer. Lewis will lead and build the marketing efforts for both existing ...
... viral for bacterial infections, review found , MONDAY, ... one who can,t always tell if your child has ... for antibiotics: Pediatricians say this is the most common ... Other common missed or mistaken diagnoses include those involving ...
... and cost-effective when targeted to high-risk patients, according ... the official journal of the American Gastroenterological Association ... be excessively costly or even harmful. "Surveillance ... that has the potential to decrease the burden ...
... something is due to our genes and how much is ... academic journal Addiction shows that the case is ... drugs, for two related reasons. First, a young woman ... to choose friends who smoke, drink, or use drugs, thereby ...
... in the journal Addiction reveals that drunkenness increases ... a strong inclination to suppress anger. The two ... reduces the risk of drawing erroneous conclusions about cause and ... of evidence suggesting that drinking may in fact inflict physical ...
... ... because of a small number of adverse event reports received by the FDA from users ... and its safety if used as directed. , ... (PRWEB) June 21, 2010 -- EphedrineHydrochloride.com is pleased to announce ...
Cached Medicine News:Health News:DKI Direct Appoints Greg Lewis as Chief Marketing Officer 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 2Health News:More Than Half of Pediatricians Make Diagnostic Errors: Survey 3Health News:Surveillance colonoscopy should be targeted to high-risk patients 2Health News:New research shows peer drug use may increase an individual's genetic tendency to use drugs 2Health News:Ephedrine Hydrochloride.com Launches Review Site Examining Ephedrine HCL & Ephedra Based Diet Pills 2
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
For the qualitative detection of Wuchereria bancrofti antigen in whole blood, serum and plasma specimens...
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
Medicine Products: